Literature DB >> 2178937

Dopamine transporter: biochemistry, pharmacology and imaging.

M J Kuhar1, P M Sanchez-Roa, D F Wong, R F Dannals, D E Grigoriadis, R Lew, M Milberger.   

Abstract

In recent years, there has been substantial progress in studying the dopamine transporter, a unique component of the functioning dopaminergic nerve terminal. The transporter has been studied by direct binding techniques using a variety of ligands which function as inhibitors of transport. Analogues of these ligands have been used as photoaffinity labels to solubilize and further characterize the transporter. While a variety of drugs bind to the transporter, it is clear that the transporter may serve as an important drug receptor, particularly for the reinforcing properties of some psychostimulants such as cocaine. An extension of the in vitro ligand-binding studies reveals that it is possible to preferentially label the transporter in vivo. The success of in vivo labeling has lead to successful positron emission tomographic scanning studies of the transporter. These studies in turn have revealed the usefulness of imaging the transporter, a measure of the presence of dopaminergic nerve terminals, as a potential diagnostic tool in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2178937     DOI: 10.1159/000117169

Source DB:  PubMed          Journal:  Eur Neurol        ISSN: 0014-3022            Impact factor:   1.710


  10 in total

1.  Enhanced responsiveness to novelty and cocaine is associated with decreased basal dopamine uptake and release in the nucleus accumbens: quantitative microdialysis in rats under transient conditions.

Authors:  Vladimir I Chefer; Irina Zakharova; Toni S Shippenberg
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

2.  Neuroleptics and dopamine transporters.

Authors:  T A Reader; A R Ase; N Huang; C Hébert; N M van Gelder
Journal:  Neurochem Res       Date:  1998-01       Impact factor: 3.996

3.  Behavioral and neurochemical changes in the dopaminergic system after repeated cocaine administration.

Authors:  L H Claye; H C Akunne; M D Davis; S DeMattos; K F Soliman
Journal:  Mol Neurobiol       Date:  1995 Aug-Dec       Impact factor: 5.590

4.  (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism.

Authors:  Gunasingh Masilamoni; John Votaw; Leonard Howell; Rosa M Villalba; Mark Goodman; Ronald J Voll; Jeffrey Stehouwer; Thomas Wichmann; Yoland Smith
Journal:  Exp Neurol       Date:  2010-09-09       Impact factor: 5.330

5.  Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.

Authors:  D F Wong; J C Harris; S Naidu; F Yokoi; S Marenco; R F Dannals; H T Ravert; M Yaster; A Evans; O Rousset; R N Bryan; A Gjedde; M J Kuhar; G R Breese
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

6.  Preparation of a potential positron emission tomographic radioligand for the dopamine transporter.

Authors:  L Müller; C Halldin; C Foged; P Karlsson; H Hall; C G Swahn; P D Suzdak; R Hohlweg; E B Nielsen; L Farde
Journal:  Eur J Nucl Med       Date:  1994-02

7.  Initial experience with single-photon emission tomography using iodine-123-labelled 2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane in human brain.

Authors:  J T Kuikka; K A Bergström; E Vanninen; V Laulumaa; P Hartikainen; E Länsimies
Journal:  Eur J Nucl Med       Date:  1993-09

8.  A model of the sodium dependence of dopamine uptake in rat striatal synaptosomes.

Authors:  D D Wheeler; A M Edwards; B M Chapman; J G Ondo
Journal:  Neurochem Res       Date:  1993-08       Impact factor: 3.996

Review 9.  Dopamine transporter mutant mice in experimental neuropharmacology.

Authors:  Raul R Gainetdinov
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-05       Impact factor: 3.000

10.  Rate of binding of various inhibitors at the dopamine transporter in vivo.

Authors:  M Stathis; U Scheffel; S Z Lever; J W Boja; F I Carroll; M J Kuhar
Journal:  Psychopharmacology (Berl)       Date:  1995-06       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.